On this page
Back to topEdwards Lifesciences EW
Edwards Lifesciences is the 205th largest S&P 500 company by market cap, worth $58.7 billion. Its board has 10 directors, 8 of them independent. 7 other officers are on file. At 30 Jun 2026, Vanguard was its largest institutional holder, with 12.2% of the company.
- CEO
- Bernard J. Zovighian
- Chair
- Nicholas J. Valeriani
- Sector
- Health CareHealth Care Equipment
- Headquarters
- Irvine, California
- Founded
- 1958
- Market cap
- $58.7B
- 205th largest, 6 Nov 2026 close
- Price to sales
- 9.7
- Market cap over revenue
- Per employee
- $3.7M
- Market cap over employees
- Connections
- 1
- Companies sharing people
Financials
Latest quarter
Q2 2026 figures from Edwards Lifesciences' earnings release.
Filed 23 Jul 2026
- Revenue
- $1.7B
- Up 14% year over year
- Net income
- $242M
- Down 27% year over year
- Diluted EPS
- $0.42
- Down 26% year over year
- Operating income
- $513M
- Up 25% year over year
Reported figures
Figures from the release, against the same period a year earlier.
| Figure | Value | Change |
|---|---|---|
| Net sales | $1.7B | +14% |
| Gross profit margin | 77.5% | 0.0 pts |
| Operating income, net | $513M | +25% |
| Net income attributable to Edwards Lifesciences Corporation | $242M | -27% |
| Diluted EPS | $0.42 | -26% |
| Cash and cash equivalents | $2.9B | - |
| Adjusted net income | $448M | +14% |
| Adjusted diluted EPS | $0.78 | +16% |
| Adjusted gross profit margin | 77.6% | 0.0 pts |
| Adjusted operating profit margin | 30% | +1.8 pts |
| Total debt | $600M | - |
| Figure | Value | Change |
|---|---|---|
| TAVR sales | $1.3B | +11% |
| TMTT sales | $199M | +48% |
| Surgical sales | $284M | +6.5% |
| United States sales | $1.0B | +13% |
| Europe sales | $440M | +16% |
| Japan sales | $96M | +1.1% |
| Rest of World sales | $202M | +19% |
| Figure | Value | Change |
|---|---|---|
| Total company sales growth guidance (constant currency)FY 2026 outlook | 10.5% | - |
| TAVR sales growth guidance (constant currency)FY 2026 outlook | 8.5% | - |
| TMTT sales guidanceFY 2026 outlook | $770M | - |
| Total company sales guidanceFY 2026 outlook | $6.8B | - |
| TAVR sales guidanceFY 2026 outlook | $4.9B | - |
| Adjusted EPS guidanceFY 2026 outlook | $3.00 | +17% |
| Total sales guidanceQ3 2026 outlook | $1.7B | - |
| Adjusted EPS guidanceQ3 2026 outlook | $0.74 | - |
| Figure | Value | Change |
|---|---|---|
| Share repurchase authorization remaining | $1.5B | - |
Financial history
Twelve months to 30 Sep 2026, from Edwards Lifesciences' quarterly filings.
Quarters since Dec 2021
- Revenue
- $6.7B
- Up 13% on the year before
- Net income
- $1.0B
- 15.3% of revenue
- Free cash flow
- $1.4B
- Operating cash flow less capital spending
- P/E
- 57.5
- Market cap over net income
Quarterly results
Each quarter's revenue, net income and free cash flow.
Dec 2021 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $1.7B | $308M |
| Jun 2026 | $1.7B | $242M |
| Mar 2026 | $1.6B | $381M |
| Dec 2025 | $1.6B | $91M |
| Sep 2025 | $1.6B | $291M |
| Jun 2025 | $1.5B | $333M |
| Mar 2025 | $1.4B | $358M |
| Dec 2024 | $1.4B | $386M |
| Sep 2024 | $1.4B | $3.1B |
| Jun 2024 | $1.4B | $366M |
| Mar 2024 | $1.6B | $352M |
| Dec 2023 | $1.5B | $370M |
| Sep 2023 | $1.5B | $385M |
| Jun 2023 | $1.5B | $307M |
| Mar 2023 | $1.5B | $341M |
| Dec 2022 | $1.3B | $398M |
| Sep 2022 | $1.3B | $344M |
| Jun 2022 | $1.4B | $406M |
| Mar 2022 | $1.3B | $374M |
| Dec 2021 | $1.3B | $335M |
Per employee
Twelve months to 30 Sep 2026, over 16,000 employees in Edwards Lifesciences' latest 10-K.
- Revenue
- $417K
- Operating profit
- $90K
- 21.6% of revenue
- Net income
- $64K
- 15.3% of revenue
Edwards Lifesciences' market cap since December 2008
Weekly, up to 6 Nov 2026
| Week ending | Market cap |
|---|---|
| 6 Nov 2026 | $58.7B |
| 26 Dec 2025 | $50.4B |
| 27 Dec 2024 | $44.6B |
| 29 Dec 2023 | $46.3B |
| 30 Dec 2022 | $46.1B |
| 31 Dec 2021 | $80.9B |
| 25 Dec 2020 | $55.2B |
| 27 Dec 2019 | $48.9B |
| 28 Dec 2018 | $31.4B |
| 29 Dec 2017 | $23.9B |
| 30 Dec 2016 | $20.0B |
| 25 Dec 2015 | $17.1B |
| 26 Dec 2014 | $13.9B |
| 27 Dec 2013 | $7.2B |
| 28 Dec 2012 | $10.3B |
| 30 Dec 2011 | $8.1B |
| 31 Dec 2010 | $9.2B |
| 25 Dec 2009 | $4.9B |
| 26 Dec 2008 | $3.0B |
Download Edwards Lifesciences' data as JSON, with the weekly market caps in billions of dollars from 5 Dec 2008.
Board and leadership
Board and officers
1 person here also holds roles at other S&P 500 companies.
Board from the proxy filed 26 Mar 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (10) | |||||
| Nicholas J. ValerianiChairIndependent · since 2014 · Compensation and GovernanceFormer CEO, Gary and Mary West Health Institute Former EVP, Johnson & Johnson | |||||
| Bernard J. ZovighianCEONot independent · since 2023 | |||||
| Leslie C. DavisDirectorIndependent · since 2024 · Compensation and GovernanceCEO and President, University of Pittsburgh Medical Center | |||||
| David T. FeinbergDirectorIndependent · since 2024 · AuditChairman, Oracle Health, Inc.Also at Humana | |||||
| Kieran GallahueDirectorIndependent · since 2015 · AuditFormer Chairman and CEO, CareFusion CorporationOther boards: Envista Holdings | |||||
| Leslie S. HeiszDirectorIndependent · since 2016 · Audit (chair)Former Managing Director, Lazard Frères & CoOther boards: Ingram Micro Holding | |||||
| Paul A. LavioletteDirectorIndependent · since 2020 · Compensation and Governance (chair)CEO, Pulse Biosciences, Inc., Managing Partner and COO, SV Health Investors LLCOther boards: Pulse Biosciences | |||||
| Steven R. LorangerDirectorIndependent · since 2016 · Compensation and GovernanceFormer Chairman, President and CEO , ITT Corporation | |||||
| Ramona SequeiraDirectorIndependent · since 2020 · AuditFormer President, Global Portfolio Division, Takeda Pharmaceutical CompanyOther boards: Organon & Co. and Novo Nordisk A/S | |||||
| Heisz Leslie StoneDirector | |||||
| Officers (7) | |||||
| Theodora MistrasCVP, Chief Financial OfficerLast filed 10 Jul 2026 | |||||
| Donald E. Bobo Jr.CVP,Strategy/Corp DevelopmentLast filed 27 May 2026 | |||||
| Annette BrulsCvp, EmeaclaLast filed 28 Aug 2026 | |||||
| Daveen ChopraCVP, TMTT, Surgical & IHFMLast filed 11 Sep 2026 | |||||
| Andrew M. DahlSVP, Corporate ControllerLast filed 14 Sep 2026 | |||||
| Daniel J. LippisCvp, TavrLast filed 11 Sep 2026 | |||||
| Wayne MarkowitzCvp, JapacLast filed 14 Sep 2026 | |||||
Companies that share people with Edwards Lifesciences
Each person's title here, then at the other company.
- Humana HUM
- David T. Feinberg: Director here, Director there
Owners and trading
Largest institutional holders
Each fund group's share of Edwards Lifesciences. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 6 Nov 2025 to 6 Nov 2026
Directors and officers sold $27.7 million of stock in 43 sales and made no open-market purchases in the 12 months to 6 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 8 Oct 2026Sale | Daniel J. LippisCvp, Tavr | $53K |
| 11 Sep 2026Sale | Daniel J. LippisCvp, Tavr | $54K |
| 31 Aug 2026Sale | Andrew M. DahlSVP, Corporate Controller | $50K |
| 28 Aug 2026Sale | Annette BrulsCvp, Emeacla | $238K |
| 26 Aug 2026Sale | Daveen ChopraCVP, TMTT, Surgical & IHFM | $2.9M |
| 26 Aug 2026Sale | Wayne MarkowitzCvp, Japac | $113K |
| 11 Aug 2026Sale | Daniel J. LippisCvp, Tavr | $57K |
| 30 Jul 2026Sale | Wayne MarkowitzCvp, Japac | $13K |
| 28 Jul 2026Sale | Wayne MarkowitzCvp, Japac | $819K |
| 27 Jul 2026Sale | Bernard J. ZovighianCEO | $245K |
Showing 10 of 43 trades
Trades by members of Congress and officials
Trades members of Congress and senior executive branch officials disclosed, including their families'. Amounts are filed as ranges.
Trades from 27 Oct 2023 to 27 Oct 2026
10 people disclosed 9 purchases and 11 sales of Edwards Lifesciences stock since October 2023.
| Date | Member or official | Amount |
|---|---|---|
| 3 Aug 2026 | Rohit KhannaHouse, D-CA · Sold | $1K to $15K |
| 11 May 2026 | Donald J TrumpPresident · Bought | $50K to $100K |
| 13 Apr 2026 | Rohit KhannaHouse, D-CA · Bought | $1K to $15K |
| 10 Apr 2026 | Donald J TrumpPresident · Sold | $100K to $250K |
| 27 Mar 2026 | Alan ArmstrongSenate, R-OK · Bought | $1K to $15K |
| 10 Feb 2026 | Donald J TrumpPresident · Bought | $500K to $1M |
| 23 Jan 2026 | Rohit KhannaHouse, D-CA · Sold | $1K to $15K |
| 13 Jan 2026 | Rohit KhannaHouse, D-CA · Sold | $1K to $15K |
| 19 Nov 2025 | Josh GottheimerHouse, D-NJ · Sold | $1K to $15K |
| 7 Oct 2025 | Rohit KhannaHouse, D-CA · Sold | $1K to $15K |
Showing 10 of 20 trades
Workforce and hiring
Workforce
Headcount at 31 Dec 2025
- Employees
- 16,000
Employees, last 10 fiscal years
Up 7.4% in five years, from 14,900 in 2020 to 16,000 in 2025.
As of December 31, 2025, we had approximately 16,000 employees worldwide, the majority of whom were located in the United States, Singapore, and Costa Rica.
Open roles
Jobs listed on Edwards Lifesciences' careers site, each counted once.
Daily, up to 3 Nov 2026
- Open roles
- 358
- On 3 Nov 2026
- Change
- -21
- Down 5.5% since 27 Oct 2026
- Top function
- Sales & Marketing
- 30% of open roles
- Remote
- 6%
- 92% do not say
Open roles in detail
27 Oct 2026 to 3 Nov 2026
Most are in the US (39%), then China and India.
| Role | Posted |
|---|---|
| Account Manager (Kaohsiung/Tainan)Taiwan-Taipei | 3 Nov 2026 |
| Analyst, Accounts PayableMalaysia-Kuala Lumpur BSC | 3 Nov 2026 |
| Analyst, Sales Operations THVSpain-Valencia; Spain-Madrid-Remote; Spain-Barcelona-Remote | 3 Nov 2026 |
| Field Clinical Specialist (TAVI)United Kingdom-Field | 3 Nov 2026 |
| Medical Science Liaison Manager - UKUnited Kingdom-Field | 3 Nov 2026 |
| Product Manager, Upstream Marketing TMVR Global MarketingUSA - California – Irvine | 3 Nov 2026 |
| Quality Engineer ISpain-Valencia | 3 Nov 2026 |
| Quality Systems & CAPA Engineer IIUSA - California – Irvine | 3 Nov 2026 |
| Day | Open roles |
|---|---|
| 3 Nov 2026 | 358 |
| 2 Nov 2026 | 359 |
| 1 Nov 2026 | 369 |
| 31 Oct 2026 | 370 |
| 30 Oct 2026 | 375 |
| 29 Oct 2026 | 375 |
| 28 Oct 2026 | 381 |
| 27 Oct 2026 | 379 |
WARN layoff notices
Notices filed under Edwards Lifesciences' own name or a subsidiary's listed in its 10-K.
Notices from 7 Nov 2023 to 7 Nov 2026
Edwards Lifesciences filed 2 notices covering 193 workers since November 2023.
| Notice | Place | Workers |
|---|---|---|
| 4 Sep 2024 | Irvine, CA | 192 |
| 4 Sep 2024 | Santa Ana, CA | 1 |
Timeline
Leadership changes, layoffs and insider sales
7 Nov 2024 to 7 Nov 2026; insider sales from 6 Nov 2025
3 departures and 2 appointments of directors and officers and 11 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Edwards Lifesciences' insider sales.
Events, newest first
- 26 Aug 2026 Daveen Chopra sold $2.9MCVP, TMTT, Surgical & IHFM
- 25 Aug 2026 Donald E. Bobo, Jr. retiredCorporate Vice President, Strategy and Corporate Development
- 27 May 2026 Donald E. Bobo Jr. sold $2.0MCVP,Strategy/Corp Development
- 15 May 2026 Donald E. Bobo Jr. sold $1.5MCVP,Strategy/Corp Development
- 12 May 2026 Bernard J. Zovighian sold $2.8MCEO
- 2 May 2026 Theodora Mistras appointedCorporate Vice President, Chief Financial Officer, effective 29 May 2026
- 9 Apr 2026 Scott B. Ullem sold $1.0MCVP, Chief Financial Officer
- 2 Apr 2026 Donald E. Bobo Jr. sold $1.8MCVP,Strategy/Corp Development
Showing 8 of 16 events
| Date | Event | Filing |
|---|---|---|
| 26 Aug 2026 | Daveen Chopra sold $2.9MCVP, TMTT, Surgical & IHFM | Form 4 |
| 25 Aug 2026 | Donald E. Bobo, Jr. retiredCorporate Vice President, Strategy and Corporate Development | 8-K |
| 27 May 2026 | Donald E. Bobo Jr. sold $2.0MCVP,Strategy/Corp Development | Form 4 |
| 15 May 2026 | Donald E. Bobo Jr. sold $1.5MCVP,Strategy/Corp Development | Form 4 |
| 12 May 2026 | Bernard J. Zovighian sold $2.8MCEO | Form 4 |
| 2 May 2026 | Theodora Mistras appointedCorporate Vice President, Chief Financial Officer, effective 29 May 2026 | 8-K |
| 9 Apr 2026 | Scott B. Ullem sold $1.0MCVP, Chief Financial Officer | Form 4 |
| 2 Apr 2026 | Donald E. Bobo Jr. sold $1.8MCVP,Strategy/Corp Development | Form 4 |
| 11 Mar 2026 | Scott B. Ullem sold $1.1MCVP, Chief Financial Officer | Form 4 |
| 25 Feb 2026 | Donald E. Bobo Jr. sold $2.0MCVP,Strategy/Corp Development | Form 4 |
| 12 Feb 2026 | Bernard J. Zovighian sold $1.7MCEO | Form 4 |
| 8 Dec 2025 | Bernard J. Zovighian sold $1.8MCEO | Form 4 |
| 10 Nov 2025 | Scott B. Ullem sold $1.1MCVP, Chief Financial Officer | Form 4 |
| 30 Oct 2025 | Scott Ullem resignedChief Financial Officer, effective 29 May 2026 | 8-K |
| 21 Jul 2025 | Larry L. Wood resignedCorporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart, effective 1 Sep 2025 | 8-K |
| 21 Jul 2025 | Daniel J. Lippis appointedCorporate Vice President responsible for Transcatheter Aortic Valve Replacement, effective 1 Sep 2025 | 8-K |